【美股异动 | 再鼎医药(ZLAB.US)涨逾2% 在研ADC ZociⅠb期数据积极】智通财经APP获悉,周五,再鼎医药(ZLAB.US)盘初一度涨近10%,截至发稿,涨逾2%,报22.62美元。消息面上,10月23日,再鼎医药公布了旗下在研抗体偶联药物(ADC)Zocilurtatug
Pelitecan(简称“Zoci”,原代号ZL-1310)用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。相关结果将于10月26日在2026年欧洲肿瘤内科学会(ESMO)大会上展示。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.